Skip to main content

AIDS

11
Pipeline Programs
8
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
5
0
1
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
6100%
+ 8 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
5 programs
1
3
1
MaravirocPhase 4
GSK Biologicals HIV Vaccine 732462Phase 2Vaccine
GSK Biologicals' HIV vaccinePhase 2Vaccine
HIV vaccine 732461Phase 2Vaccine
HIV Vaccine 732462Phase 1Vaccine
MSD
MSDIreland - Ballydine
2 programs
1
1
CompliancePhase 41 trial
Trivalent MRKAd5 HIV-1 gag/pol/nefPhase 21 trial
Active Trials
NCT00095576Terminated3,000Est. Sep 2009
NCT00207168Completed120Est. Dec 2006
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
1
1
CompliancePhase 4
Trivalent MRKAd5 HIV-1 gag/pol/nefPhase 2
Pfizer
PfizerNEW YORK, NY
1 program
1
MaravirocPhase 4
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
1
nevirapinePhase 31 trial
Active Trials
NCT00117728Unknown250Est. Sep 2010
GSK
GSKLONDON, United Kingdom
2 programs
GSK Biologicals' HIV vaccinePHASE_2Vaccine1 trial
HIV vaccine 732461PHASE_2Vaccine1 trial
Active Trials
NCT00972725Completed28Est. Oct 2010
NCT00434512Completed180Est. Jun 2008
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
CompliancePHASE_4

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MSDCompliance
Human BioSciencesnevirapine
GSKGSK Biologicals' HIV vaccine
GSKHIV vaccine 732461
MSDTrivalent MRKAd5 HIV-1 gag/pol/nef

Clinical Trials (5)

Total enrollment: 3,578 patients across 5 trials

NCT00207168MSDCompliance

To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine

Start: Apr 2004Est. completion: Dec 2006120 patients
Phase 4Completed
NCT00117728Human BioSciencesnevirapine

Pediatric Nevirapine Resistance Study

Start: Apr 2005Est. completion: Sep 2010250 patients
Phase 3Unknown
NCT00972725GSKGSK Biologicals' HIV vaccine

Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose

Start: Dec 2009Est. completion: Oct 201028 patients
Phase 2Completed
NCT00434512GSKHIV vaccine 732461

Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers

Start: Feb 2007Est. completion: Jun 2008180 patients
Phase 2Completed
NCT00095576MSDTrivalent MRKAd5 HIV-1 gag/pol/nef

Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023)

Start: Nov 2004Est. completion: Sep 20093,000 patients
Phase 2Terminated

Related Jobs

Medical Advisor - Vaccines/Infectious Disease

Merck & Co.Merck & Co.
SWE - Stockholm - Stockholm (Gavlegatan) (Not Applicable)
2w ago

Regional Director, Medical Affairs, HIV, EEMEA

Merck & Co.Merck & Co.
Remote
2w ago

HIV Customer Representative - Sacramento, CA

Merck & Co.Merck & Co.
Remote
2w ago
$106K - $167K/yr

Senior Specialist, Manufacturing Automation

Merck & Co.Merck & Co.
USA - Pennsylvania - West Point (Hybrid)
2w ago
$117K - $184K/yr

Director, Infectious Diseases and Vaccines, Quantitative Pharmacology and Pharmacometrics

Merck & Co.Merck & Co.
USA - Pennsylvania - West Point; USA - New Jersey - Rahway (Hybrid)
3w ago
$191K - $300K/yr

HIV Customer Representative - Allentown, PA

Merck & Co.Merck & Co.
Remote
3w ago
$106K - $167K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.